AI Article Synopsis
- Ocrelizumab, an anti-CD20 monoclonal antibody, is used to treat multiple sclerosis but may increase the risk of infections due to its effect on B-cells and related factors like BAFF, APRIL, and CD40L.
- The study measured levels of BAFF, APRIL, and CD40L in 38 people with multiple sclerosis and 26 healthy donors at the start of treatment and at 6 and 12 months to assess their relationship with infection risk.
- Results showed that pwMS had higher levels of BAFF, APRIL, and CD40L at baseline, with BAFF levels increasing over the year, while those who had infections had consistently higher BAFF levels compared to those without infections,
Article Abstract
Background: The anti-CD20 monoclonal antibody ocrelizumab has been widely employed in the treatment of people with multiple sclerosis (pwMS). However, its B-cell-depleting effect may induce a higher risk of infectious events and alterations in the secretion of B-cell-activating factors, such as BAFF, APRIL and CD40L.
Methods: The aim of this study was to investigate plasma BAFF, APRIL and CD40L levels and their relationship with infectious risk in ocrelizumab-treated pwMS at baseline (T0), at 6 months (T6) and at 12 months (T12) after starting the treatment. As a control group, healthy donors (HD) were enrolled too.
Results: A total of 38 pwMS and 26 HD were enrolled. At baseline, pwMS showed higher plasma BAFF ( < 0.0001), APRIL ( = 0.0223) and CD40L ( < 0.0001) levels compared to HD. Compared to T0, plasma BAFF levels were significantly increased at both T6 and T12 ( < 0.0001 and < 0.0001, respectively). Whereas plasma APRIL and CD40L levels were decreased at T12 ( = 0.0003 and < 0.0001, respectively). When stratifying pwMS according to the development of an infectious event during the 12-month follow-up period in two groups-with (14) and without an infectious event (24)-higher plasma BAFF levels were observed at all time-points; significantly, in the group with an infectious event compared to the group without an infectious event (T0: < 0.0001, T6: = 0.0056 and T12: = 0.0400). BAFF may have a role as a marker of immune dysfunction and of infectious risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135639 | PMC |
| http://dx.doi.org/10.3390/biology12040587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of class-switched B cells in chickens.
Front Immunol
December 2024
Department of Veterinary Sciences, AG Immunology, Ludwig-Maximilians-Universität München, Planegg, Germany.
While B cell development in the birds' primary B cell organ, the bursa Fabricius, is relatively well understood, very little is known about post bursal B cell differentiation into plasma and memory cells though these cells are essential for a protecting antibody response and so far, no specific markers for these cells were available. Since immunoglobulin class switch is one part of the B cell differentiation process, our objective was to conduct a first detailed investigation of class-switched chicken B cells. As only very few IgY and IgA expressing cells were detected in lymphoid organs of young chickens, we used CD40L and IL-10 to establish a prolonged culture system, which induces B cell proliferation, class switch to IgY and IgA and enhanced antibody secretion.
View Article and Find Full Text PDFMulti-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
J Neurol Sci
December 2024
Institute for Systems Biology, WA, USA. Electronic address:
The study examined changes in the plasma proteome, metabolome, and lipidome of N = 14 patients with relapsing-remitting multiple sclerosis (RRMS) initiating treatment with ocrelizumab, assayed at baseline, 6 months, and 12 months. Analyses of >4000 circulating biomarkers identified depletion of B-cell associated proteins as the early effect observed following ocrelizumab (OCR) initiation, accompanied by the reduction in plasma abundance of cytokines and cytotoxic proteins, markers of neuronaxonal damage, and biologically active lipids including ceramides and lysophospholipids, at 6 months. B-cell depletion was accompanied by decreases in B-cell receptor and cytokine signaling but a pronounced increase in circulating plasma B-cell activating factor (BAFF).
View Article and Find Full Text PDFCXCL13/CXCR5 axis facilitates TFH expansion and correlates with disease severity in adults with immune thrombocytopenia.
Thromb Res
December 2024
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fujian Medical University, Fuzhou, Fujian, China; School of Medical Imaging, Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address:
Background: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder defined by a diminished platelet count. ITP pathogenesis involves intricate changes to both cellular and humoral immunity. The pivotal roles of follicular helper T (TFH) cells in the maturations of B cells and the production of antibodies are well-established.
View Article and Find Full Text PDFB-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
Int J Mol Sci
October 2024
Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Article Synopsis
- The BAFF-APRIL system is important in systemic lupus erythematosus (SLE) as it helps B cells survive and contribute to autoimmunity; this study examined BCMA expression in B cell subsets in SLE patients and healthy controls.
- SLE patients showed higher BCMA expression on B cells compared to healthy controls, with notable increases in memory B cells and a correlation between BCMA levels and disease markers like anti-dsDNA antibodies.
- Belimumab treatment reduced BCMA expression and other components of the BAFF-APRIL system, indicating its potential as both a treatment strategy and a biomarker for monitoring disease activity in SLE.
New Insights and Future Perspectives of APRIL in IgA Nephropathy.
Int J Mol Sci
September 2024
Department of Nephrology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan.
Article Synopsis
- IgA nephropathy (IgAN) is an immune-related kidney disease caused by the buildup of a specific type of IgA in the kidney glomeruli, leading to various symptoms and a lack of effective treatments due to incomplete understanding of its mechanisms.
- Recent research identifies the cytokine APRIL as a key player in the production of the problematic IgA1 in IgAN, revealing new potential treatment avenues.
- Initial studies on APRIL-targeting therapies show promise in reducing harmful protein levels in the urine and improving patient outcomes, suggesting potential new treatments for IgAN.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!